Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Is Driven By Growing Incidences Of Neuroendocrine Tumors
Peptide receptor radionuclide therapy or PRRT is a type of cancer treatment that combines peptides tagged with radioactive elements or radiopharmaceuticals. PRRT involves the use of radiolabeled molecules that target receptors on cancer cells. These receptors overexpress on neuroendocrine tumors which enables the targeting of cancer cells. The radioisotopes delivered by the peptides allows for both diagnostic imaging and cancer cell killing.
The Global Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is estimated to be valued at US$ 681.79 Mn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Italy Peptide Receptor Radionuclide Therapy (PRRT) are Beverage Air, Dover Corporation, Hussmann Corporation, Able Products, Precision Refrigeration, Nor-Lake, Infrico, TSSC, Ali Group, UKB. The growing demand for PRRT as a therapeutic option for neuroendocrine tumors is one of the major factors driving the market growth. The favorable reimbursement scenario for PRRT procedures in Italy further supplements the demand. Rapid expansion of clinical trials evaluating the efficacy of PRRT against various cancer types is also fueling the market expansion.
The increasing incidence and prevalence of neuroendocrine tumors globally is propelling the Italy PRRT market. According to recent estimates, the annual incidence of NETs in Europe is approximately 5 per 100,000 people. Furthermore, the approval and adoption of novel peptides and radioisotopes are expanding the applications of PRRT. Various regulatory approvals for clinical indications are also supporting the revenue generation.
Market drivers
The primary driver for the Italy PRRT Market Analysis is the rising burden of neuroendocrine tumors. Neuroendocrine tumors have an annual incidence rate of approximately 6 per 100,000 people in Western countries. Among all gastrointestinal cancers in Italy, NETs account for approximately 2%. The high unmet clinical need for advanced and metastatic NETs is also significantly driving the demand for PRRT as an effective therapeutic alternative. Furthermore, ongoing research to expand the available indications and development of newer targeted radiopharmaceuticals are expected to propel the Italy PRRT market over the coming years.
Impact of Geopolitical Situation on Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Growth
The current geopolitical instability and economic uncertainty across major global regions is negatively impacting the growth of Italy's Peptide Receptor Radionuclide Therapy (PRRT) market. The ongoing Russia-Ukraine conflict and rising tensions between Western nations and China have disrupted international trade and supply chains. This has led to shortages of key raw materials and components required for PRRT therapies. The volatility in global energy prices and rising inflation are also lowering consumer spending power which can decrease the demand for expensive medical therapies in the coming years.
To sustain growth, market players must focus on diversifying their supply sources and establishing strategic partnerships within Italy and other European countries. Strengthening local manufacturing capabilities can help reduce dependency on imports. Companies also need to invest more in research to develop affordable treatment options. The Italian government should provide tax incentives and relaxation in regulations to boost indigenous production. While challenges remain, the demand for effective cancer therapies within the aging Italian population is likely to support steady market expansion if appropriate strategies are adopted to navigate the volatile external environment.
Regions with High Concentration of Italy Peptide Receptor Radionuclide Therapy (PRRT) Market by Value
The two regions accounting for the highest market value in Italy's PRRT industry are Northern and Central Italy. Together they account for over 65% of the national market in terms of revenue.
Northern Italy has consistently been the revenue leader due to the presence of several key market players, universities, and hospitals offering nuclear medicine facilities in major cities like Milan, Turin and Genoa. Strong economic conditions in this wealthy region translate to greater affordability and uptake of innovative cancer therapies.
Central Italy, comprising Rome and the surrounding areas, generates significant demand as many patients travel to the capital for advanced treatment options. Apart from metropolitan centers, growing procurement by hospitals across Tuscany and Umbria is also driving the market in Central Italy.
Fastest Growing Region in the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market
Southern Italy is expected to witness the fastest market growth during the forecast period. Although this region has a smaller current market value than North or Central Italy, factors like improving healthcare infrastructure, rising cancer incidence, and efforts to reduce wait times for specialized care are positively impacting adoption.
In particular, major transplant and oncology facilities in cities like Naples, Bari and Palermo have boosted nuclear medicine capabilities and are undertaking more PRRT procedures. Initiatives by the regional governments to boost access through subsidized insurance schemes in poorer areas are also contributing to higher than average annual growth rates across Campania, Apulia, Sicily, Calabria and Sardinia. In the coming years, Southern Italy is likely to emerge as one of the fastest growing geographic markets for PRRT therapies in the country.
Get More Insights On Italy Peptide Receptor Radionuclide Therapy (PRRT) Market
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian